177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Trial Details

NCT ID
NCT07189871
Phase
PHASE1 / PHASE2
Sponsor
Radiopharm Theranostics, Ltd
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • 177Lu-BetaBart
Locations (sample)
  • Dothan, Alabama, United States|31.22323,-85.39049
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Willing and able to provide informed consent prior to start of any study procedures and assessments and must be willing to comply with all study pr…
  • Participants ≥ 18 years of age.
  • Participants with a documented history of histopathologically confirmed CRPC\*, CRC, NSCLC, SCLC, HNSCC, ovarian cancer, cervical cancer, endometri…
  • a. \*Progressive CRPC defined as castrate levels of testosterone and progressing by at least one of the following criteria: i. Serum PSA progressio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →